Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McMaster University

$27,000.00

Investigating a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) as a novel therapeutic for sepsis

FY 2025-26

Summary
Sepsis is a life-threatening condition caused by a large immune response to infection. Sepsis is responsible for ~11 million deaths worldwide each year. Not only is sepsis of global concern, but Canada is also impacted. Nationally, those hospitalized with severe sepsis are at a 66% higher risk of death than hospitalized patients without sepsis. One of the complications during sepsis is increased blood clotting, which can impair organ function and lead to death. There is a protein in the blood called VWF, which stands for Von Willebrand Factor. VWF is a protein that enhances blood clotting, which may worsen the septic condition. There is another protein in the blood called ADAMTS13, which stands for a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13. ADAMTS13 cuts VWF and prevents excessive blood clotting. Decreased ADAMTS13 levels are seen in sepsis cases with poor patient outcomes, which indicates that increasing ADAMTS13 activity may be beneficial to treat sepsis. We hypothesize that ADAMTS13 will improve sepsis outcomes by preventing organ damage and unwanted blood clotting. To test our hypothesis in mice, we will mimic sepsis from a bacterial infection and then administer ADAMTS13 intravenously. We will monitor the mice for signs of distress and sepsis throughout the entire study. First, we will identify the best time and dose to administer ADAMTS13 and prevent death. Then, we will investigate how ADAMTS13 helps survival. From mouse samples, will measure signs of blood clotting, organ function, immune system activity, levels of bacteria, as well as the levels and activity of ADAMTS13. If ADAMTS13 is effective in septic mice, this study may lead to human-based research, and to the implementation of a new sepsis treatment.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572543
Name
Sisk Bailey
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) as a novel therapeutic for sepsis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Adamts13; Bacterial Infection; Blood Coagulation; Drug Therapy; Hospitalization; Immunothrombosis; Mouse Study; Sepsis; Sex Differences; Vwf
Abstract
Sepsis is a life-threatening condition caused by a large immune response to infection. Sepsis is responsible for ~11 million deaths worldwide each year. Not only is sepsis of global concern, but Canada is also impacted. Nationally, those hospitalized with severe sepsis are at a 66% higher risk of death than hospitalized patients without sepsis. One of the complications during sepsis is increased blood clotting, which can impair organ function and lead to death. There is a protein in the blood called VWF, which stands for Von Willebrand Factor. VWF is a protein that enhances blood clotting, which may worsen the septic condition. There is another protein in the blood called ADAMTS13, which stands for a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13. ADAMTS13 cuts VWF and prevents excessive blood clotting. Decreased ADAMTS13 levels are seen in sepsis cases with poor patient outcomes, which indicates that increasing ADAMTS13 activity may be beneficial to treat sepsis. We hypothesize that ADAMTS13 will improve sepsis outcomes by preventing organ damage and unwanted blood clotting. To test our hypothesis in mice, we will mimic sepsis from a bacterial infection and then administer ADAMTS13 intravenously. We will monitor the mice for signs of distress and sepsis throughout the entire study. First, we will identify the best time and dose to administer ADAMTS13 and prevent death. Then, we will investigate how ADAMTS13 helps survival. From mouse samples, will measure signs of blood clotting, organ function, immune system activity, levels of bacteria, as well as the levels and activity of ADAMTS13. If ADAMTS13 is effective in septic mice, this study may lead to human-based research, and to the implementation of a new sepsis treatment.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sisk, Bailey
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~